Hepatotoxicity associated with herbal remedies: Clinical, biological, histological data and the mechanisms involved in some typical examples;Hépatotoxicité de la phytothérapie: Données cliniques, biologiques, histologiques et mécanismes en cause pour quelques exemples caractéristiques

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 6-7 I, 2004, Pages 540-550

  Peyrin Biroulet, Laurent ^a   Barraud, Hélène ^a   Petit Laurent, Fabien ^a   Ancel, David ^a   Watelet, Jérôme ^a   Chone, Laurence ^a   Hudziak, Hervé ^a   Bigard, Marc André ^a   Bronowicki, Jean Pierre ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTRACTYLIS GUMMIFERA EXTRACT; CALLILEPIS LAUREOLA EXTRACT; EXOLISE; GREEN TEA EXTRACT; HERBACEOUS AGENT; KAVA EXTRACT; LYCOPUS SERRATUM EXTRACT; PLANT EXTRACT; PYRROLIZIDINE ALKALOID; TEALINE; TEUCRIUM CHAMAEDRYS EXTRACT; UNCLASSIFIED DRUG;

CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; HERBAL MEDICINE; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; PATHOPHYSIOLOGY; PHYTOTHERAPY; REVIEW;

EID: 3142657131     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(04)95009-9     Document Type: Review

References (100)

1. Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001;135:262-8.
2. Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003;290:1505-9.
3. Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999;30:1099-104.
4. Larrey D. Hépatotoxicité: la phytothérapie aussi. Gastroenterol Clin Biol 1992;16:913-5.
5. Lemaigre G, Tebbi Z, Galinsky R, Michowitcz S, Abelanet R. Hépatite fulminante par intoxication due au chardon à glu (Atractylis glummifera-L). Étude anatomo-pathologique de 4 cas. Nouv Presse Med 1975;4:2565-8.
6. Chitturi S, Farrell GC. Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol 2000;15:1093-9.
7. Carlsson C. Herbs and hepatitis. Lancet 1990;336:1068.
8. Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003;138:852-8.
9. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002;177:440-3.
10. Lontos S, Jones RM, Angus PW, Gow PJ. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2003;179:390-1.
11. Guengerich FP. Cytochromes p450, drugs, and diseases. Mol Interv 2003;3:194-204.
12. Larrey D, Pageaux GP. Hepatotoxicity of herbal remedies and mushrooms. Semin Liver Dis 1995;15:183-8.
13. Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997;26 (Suppl 1):47-51.
14. Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003;18:451-71.
15. Pageaux GP, Larrey D. Alternative medicine, vitamins, and natural hepatotoxins. Drug-induced liver disease. Kaplowitz N, DeLeve LD (eds). New York: Dekker Publishers 2002:709-24.
16. Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002;22:195-206.
17. Larribaud J. Deux cas d'empoisonnement par le charbon à glu, Atractylis gummifera L. Observés à Dellys (Algérie). Arch Inst Pasteur Alger 1954;32:23-9.
18. Larrey D, Blanc P. Hépatotoxicité des plantes médicinales. Concours Med 2001;115:2299-303.
19. Georgiou M, Sianidou L, Hatzis T, Papadatos J, Koutselinis A. Hepatotoxicity due to Atractylis gummifera-L. J Toxicol Clin Toxicol 1988;26:487-93.
20. Skalli S, Alaoui I, Pineau A, Zaid A, Soulaymani R. Intoxication due à atractylis gummifera L.: à propos d'un cas. Bull Soc Pathol Exot 2002;95:284-6.
21. Bye SN, Dutton MF. The inappropriate use of traditional medicines in South Africa. J Ethnopharmacol 1991;34:253-9.
22. Wainwright J, Schonland MM. Toxic hepatitis in black patients in natal. S Afr Med J 1977;51:571-3.
23. Wainwright J, Schonland MM, Candy HA. Toxicity of Callilepis laureola. S Afr Med J 1977;52:313-5.
24. Watson AR, Coovadia HM, Bhoola KD. The clinical syndrome of Impila (Callilepis laureola) poisoning in children. S Afr Med J 1979;55:290-2.
25. Hutchings A, Terblanche SE. Observations on the use of some known and suspected toxic Liliiflorae in Zulu and Xhosa medicine. S Afr Med J 1989;75:62-9.
26. Obatomi DK, Bach PH. Biochemistry and toxicology of the diterpenoid glycoside atractyloside. Food Chem Toxicol 1998;36:335-46.
27. Popat A, Shear NH, Malkiewicz I, Stewart MJ, Steenkamp V, Thomson S, et al. The toxicity of Callilepis laureola, a South African traditional herbal medicine. Clin Biochem 2001;34:229-36.
28. Steenkamp V, Stewart MJ, Zuckerman M. Detection of poisoning by Impila (Callilepis laureola) in a mother and child. Hum Exp Toxicol 1999;18:594-7.
29. Stewart MJ, Steenkamp V. The biochemistry and toxicity of atractyloside: a review. Ther Drug Monit 2000;22:641-9.
30. Haouzi D, Lekehal M, Moreau A, Moulis C, Feldmann G, Robin MA, et al. Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology 2000;32:303-11.
31. Stickel F, Seitz HK. The efficacy and safety of comfrey. Public Health Nutr 2000;3:501-8.
32. Weston CF, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J 1987;295:183.
33. Bach N, Thung SN, Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med 1989;87:97-9.
34. Ridker PM, McDermott WV. Comfrey herb tea and hepatic veno-occlusive disease. Lancet 1989;1:657-8.
35. Yeong ML, Swinburn B, Kennedy M, Nicholson G. Hepatic veno-occlusive disease associated with comfrey ingestion. J Gastroenterol Hepatol 1990;5:211-4.
36. Steenkamp V, Stewart MJ, Zuckerman M. Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Ther Drug Monit 2000;22:302-6.
37. Mohabbat O, Younos MS, Merzad AA, Srivastava RN, Sediq GG, Aram GN. An outbreak of hepatic veno-occlusive disease in northwestern Afghanistan. Lancet 1976;2:269-71.
38. Tandon BN, Tandon HD, Tandon RK, Narndranathan M, Joshi YK. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976;2:271-2.
39. Tandon BN, Joshi YK, Sud R, Koshy A, Jain SK, Tandon HD. Follow-up of survivors of epidemic veno-occlusive disease in India. Lancet 1984;1:730.
40. Rasenack R, Muller C, Kleinschmidt M, Rasenack J, Wiedenfeld H. Veno-occlusive disease in a fetus caused by pyrrolizidine alkaloids of food origin. Fetal Diagn Ther 2003;18:223-5.
41. Dickinson JO, Cooke MP, King RR, Mohamed PA. Milk transfer of pyrrolizidine alkoloids in cattle. J Am Vet Med Assoc 1976;169:1192-6.
42. Deinzer ML, Thomson PA, Burgett DM, Isaacson DL. Pyrrolizidine alkaloids: their occurrence in honey from tansy ragwort (Senecio jacobaea). Science 1977;195:497-9.
43. Valla D, Benhamou JP. Drug-induced vascular and sinusoidal lesions of the liver. Baillieres Clin Gastroenterol 1988;2:481-500.
44. Kumana CR, Ng M, Lin HJ, Ko W, Wu PC, Todd D. Herbal tea induced hepatic veno-occlusive disease: quantification of toxic alkaloid exposure in adults. Gut 1985;26:101-4.
45. Huxtable RJ. New aspects of the toxicology and pharmacology of pyrrolizidine alkaloids. Gen Pharmacol 1979;10:159-67.
46. Deleve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 2003;125:882-90.
47. Mattocks AR. Toxicity of pyrrolizidine alkaloids. Nature 1968;217:723-8.
48. Yang YC, Yan J, Doerge DR, Chan PC, Fu PP, Chou MW. Metabolic activation of the tumorigenic pyrrolizidine alkaloid, riddelliine, leading to DNA adduct formation in vivo. Chem Res Toxicol 2001;14:101-9.
49. Werb Z, Hembry RM, Murphy G, Aggeler J. Commitment to expression of the metalloendopeptidases, collagenase and stromelysin: relationship of inducing events to changes in cytoskeletal architecture. J Cell Biol 1986;102:697-702.
50. MacDougall JR, Kerbel RS. Constitutive production of 92-kDa gelatinase B can be suppressed by alterations in cell shape. Exp Cell Res 1995;218:508-15.
51. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22:27-42.
52. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9.
53. Gordon GJ, Coleman WB, Grisham JW. Bax-mediated apoptosis in the livers of rats after partial hepatectomy in the retrorsine model of hepatocellular injury. Hepatology 2000;32:312-20.
54. Castot A, Larrey D. Hépatites observées au cours d'un traitement par un médicament ou une tisane contenant de la Germandrée petit-chêne. Bilan des 26 cas rapportés aux Centres Régionaux de Pharmacovigilance. Gastroenterol Clin Biol 1992;16:916-22.
55. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985;40:111-4.
56. Mostefa-Kara N, Pauwels A, Pines E, Biour M, Levy VG. Fatal hepatitis after herbal tea. Lancet 1992;340:674.
57. Dao T, Peytier A, Galateau F, Valla A. Hépatite chronique cirrhogène à la germandrée petit-chêne. Gastroenterol Clin Biol 1993;17:609-10.
58. Ben Yahia M, Mavier P, Metreau JM, Zafrani ES, Fabre M, Gatineau-Saillant G, et al. Hépatite chronique active et cirrhose induites par la germandrée petit-chêne. Trois cas. Gastroenterol Clin Biol 1993;17: 959-62.
59. Lekehal M, Pessayre D, Lereau JM, Moulis C, Fouraste I, Fau D. Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A Depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 1996;24:212-8.
60. Fau D, Lekehal M, Farrell G, Moreau A, Moulis C, Feldmann G, et al. Diterpenoids from germanden an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 1997;113:1334-46.
61. Loeper J, Descatoire V, Letteron P, Moulis C, Degott C, Dansette P, et al. Hepatotoxicity of germander in mice. Gastroenterology 1994;106:464-72.
62. Kouzi SA, McMurtry RJ, Nelson SD. Hepatotoxicity of germander (Teucrium chamaedrys L.) and one of its constituent neoclerodane diterpenes teucrin A in the mouse. Chem Res Toxicol 1994;7:850-6.
63. De Berardinis V, Moulis C, Maurice M, Beaune P, Pessayre D, Pompon D, et al. Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol 2000;58:542-51.
64. Woolf GM, Petrovic LM, Rojter SE, Wainwright S, Villamil FG, Katkov WN, et al. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med 1994;121:729-35.
65. Picciotto A, Campo N, Brizzolara R, Giusto R, Guido G, Sinelli N, et al. Chronic hepatitis induced by Jin Bu Huan. J Hepatol 1998;28:165-7.
66. Horowitz RS, Feldhaus K, Dart RC, Stermitz FR, Beck JJ. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 1996;156:899-903.
67. nde éd. Paris: Edition Lavoisier, 1993:885-7.
68. Seddik M, Lucidarme D, Creusy C, Filoche B. Y a-t-il des risques d'hépatotoxicité avec Exolise® ? Gastroenterol Clin Biol 2001;25: 834-5.
69. Peyrin-Biroulet L, Petitpain N, Kalt P, Ancel D, Petit-Laurent F, Trechot P, et al. Hépatotoxicité probable du gallate d'é pigallocatéchol utilisé en phytothérapie. Gastroenterol Clin Biol 2004;28:404-6.
70. Ruch RJ, Cheng SJ, Klaunig JE. Prevention of cytotoxicity and inhibition of intercellular communication by antioxidant catechins isolated from Chinese green tea. Carcinogenesis 1989;10:1003-8.
71. Kono S, Shinchi K, Wakabayashi K, Honjo S, Todoroki I, Sakurai Y, et al. Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. J Epidemiol 1996;6:128-33.
72. Stensvold I, Tverdal A, Solvoll K, Foss OP. Tea consumption. relationship to cholesterol, blood pressure, and coronary and total mortality. Prev Med 1992;21:546-53.
73. Kohlmeier L, Weterings KG, Steck S, Kok FJ. Tea and cancer prevention: an evaluation of the epidemiologic literature. Nutr Cancer 1997;27:1-13.
74. Lin YS, Tsai YJ, Tsay JS, Lin JK. Factors affecting the levels of tea polyphenols and caffeine in tea leaves. J Agric Food Chem 2003;51:1864-73.
75. Arts IC, van De Putte B, Hollman PC. Catechin contents of foods commonly consumed in The Netherlands. 2. Tea, wine, fruit juices, and chocolate milk. J Agric Food Chem 2000;48:1752-7.
76. Kagaya N, Tagawa Y, Nagashima H, Saijo R, Kawase M, Yagi K. Suppression of cytotoxin-induced cell death in isolated hepatocytes by tea catechins. Eur J Pharmacol 2002;450:231-6.
77. Thiolet C, Mennecier D, Bredin C, Moulin O, Rimlinger H, Nizou C, et al. Cytolyse aiguë après prise d'un thé chinois. Gastroenterol Clin Biol 2002;26:939-40.
78. Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003;178:442-3.
79. Enlow M, Spotlight ADR. Herbal hepatotoxicity. Pharmacol Toxicol 1996;21:162.
80. Campo JV, McNabb J, Perel JM, Mazariegos GV, Hasegawa SL, Reyes J. Kava-induced fulminant hepatic failure. J Am Acad Child Adolesc Psychiatry 2002;41:631-2.
81. Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001;322:139.
82. Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal remedies. Dtsch Med Wochenschr 1998;123:1410-4.
83. Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf 2002;25:251-61.
84. Kraft M, Spahn TW, Menzel J, Senninger N, Dietl KH, Herbst H, et al. Fulminates Leberversagen nach Einnahme des pflanzlichen Antidepressivums Kava-Kava. Dtsch Med Wochenschr 2001;126:970-2.
85. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001;135:68-9.
86. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products-United States, Germany, and Switzerland, 1999-2002. JAMA 2003;289:36-7.
87. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol Clin Toxicol 2003;41:109-13.
88. Cairney S, Maruff P, Clough AR, Collie A, Currie J, Currie BJ. Saccade and cognitive impairment associated with kava intoxication. Hum Psychopharmacol 2003;18:525-33.
89. Mathews JD, Riley MD, Fejo L, Munoz E, Milns NR, Gardner ID, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988;148:548-55.
90. Clough AR, Jacups SP, Wang Z, Burns CB, Bailie RS, Cairney SJ, et al. Health effects of kava use in an eastern Arnhem Land Aboriginal community. Intern Med J 2003;33:336-40.
91. Clough AR, Burns CB, Munungurr N. Kava in Arnhem Land: a review of consumption and its social correlates. Drug Alcohol Rev 2000;19:319-28.
92. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 2002;16:731-43.
93. Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS. Kava lactones and the kava-kava controversy. Phytochemistry 2003;64:673-9.
94. Schmidt TJ, Lyss G, Pahl HL, Merfort I. Helenanolide type sesquiterpene lactones. Part 5: The role of glutathione addition under physiological conditions. Bioorg Med Chem 1999;7:2849-55.
95. Bargota RS, Akhtar M, Biggadike K, Gani D, Allemann RK. Structure-activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors. Bioorg Med Chem Lett 2003;13:1623-6.
96. Wanwimolruk S, Bhawan S, Coville PF, Chalcroft SC. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Eur J Clin Pharmacol 1998;54:431-5.
97. Ernst E, Weihmayr T. UK and German media differ over complementary medicine. BMJ 2000;321:707.
98. Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: Results from a national survey. Ann Intern Med 2001;135:344-51.
99. o 86/20 bis. Paris, ministère des Affaires sociales et de l'Emploi, août 1986.
100. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-11.